Back to dashboard
CommercialAdministrativeLow impact

08.01.44c, Voretigene Neparvovec-rzyl (Luxturna®)

Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

IBX has reissued their policy for Voretigene Neparvovec-rzyl (Luxturna®), a gene therapy medication. This is a fresh reissue of an existing pharmacy policy with an effective date of April 1, 2026.

Action Required

Action needed
By April 1, 2026: Review updated Luxturna® (Voretigene Neparvovec-rzyl) policy requirements at IBX. This rare gene therapy primarily affects ophthalmology practices treating inherited retinal diseases. Billing team should verify current prior authorization and documentation requirements remain unchanged from previous policy version.

Related policy hubs